Evidence map›Paper›PMID 42084406›Full record

ArticleMicrobiology spectrum2026

SMAP29: an antibacterial peptide that possesses anti-inflammatory and fast bactericidal actions against colistin-resistant gram-negative bacteria.

Ziyue Zeng, Mengjie Wei, Deyi Zhao, Huijing Zhou, Endian Sun, Xiaowei Lv, Yuhan Yang, Tieli Zhou, Chunquan Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ziyue ZengDepartment of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University; Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, Zhejiang, China.
Mengjie WeiDepartment of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University; Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, Zhejiang, China.
Deyi ZhaoSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
Huijing ZhouSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
Endian SunDepartment of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University; Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, Zhejiang, China.
Xiaowei LvDepartment of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University; Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, Zhejiang, China.
Yuhan YangSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
Tieli ZhouDepartment of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University; Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, Zhejiang, China.ORCID 0000-0002-2171-4710
Chunquan XuDepartment of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University; Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, Zhejiang, China.ORCID 0000-0002-0259-2041

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug-resistant (MDR) gram-negative bacteria (GNB) are threatening global public health. Since colistin (COL) is the last resort antibiotic for MDR gram-negative infections, the rise in colistin-resistant ‌(COL-R) bacteria could pose risks to people. The current research investigation explored the antimicrobial, anti-biofilm, and anti-inflammatory capacities of SMAP29, a naturally generated cationic antibacterial peptide, against clinical COL-R IMPORTANCE: Multidrug-resistant gram-negative bacteria have emerged as critical threats to global public health, driving intractable infections with steadily rising incidence. These pathogens exhibit formidable tolerance to virtually all classes of contemporary antibiotics, translating into persistently high mortality and formidable clinical challenges. This study elucidates the antibacterial, anti-biofilm, and anti-inflammatory activities of the antimicrobial peptide SMAP-29 against colistin-resistant gram-negative organisms while dissecting its underlying mechanisms. Our findings provide a mechanistic framework and a promising therapeutic avenue for combating multidrug-resistant infections.

Indexed as

Anti-Bacterial AgentsAnti-Inflammatory AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesColistinGram-Negative BacteriaAcinetobacter baumanniiAnimalsBiofilmsBlood ProteinsCathelicidinsCytokinesDrug Resistance, Multiple, BacterialGram-Negative Bacterial InfectionsHumansMacrophagesAnti-Bacterial AgentsAnti-Inflammatory AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesBlood ProteinsCathelicidinsColistinCytokinesSMAP29 protein, Ovis ariesantimicrobial peptidecolistingram-negative bacteriamultidrug-resistantSMAP29

Identifiers

PMID42084406
PMCPMC13228009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.